Current Strategies for Antiplatelet Therapy in the Acute and Long-term Management of ACS
Live CME Cardiology Update Presented in Partnership with Pri-Med Institute.
Activity Overview
Dates, Locations and Speakers
Date |
Location |
Speaker |
October 13, 2010 |
Donald E. Stephens Convention Center |
Richard Lee, MD Sandeep Nathan, MD |
November 18,
2010 |
Boston Convention and Exhibition Center |
Joshua Beckman, MD Christopher Cannon, MD |
Target Audience
This activity is designed for cardiologists.
Faculty
Joshua Beckman, MD
Director, Cardiovascular Fellowship Program
Brigham and Women's Hospital
Boston, MA
Christopher Cannon, MD
Senior Investigator, TIMI Study Group Cardiovascular Division, Brigham and Women’s Hospital
Associate Professor of Medicine, Harvard Medical School
Boston, MA
Ty J. Gluckman, MD, FACC
Director, Coronary Care Unit
Providence St. Vincent Heart and Vascular Institute
Portland, OR
Richard Lee, MD
Associate Professor of Surgery, Feinberg School of Medicine
Northwestern University
Surgical Director, Center for Atrial Fibrillation,
Bluhm Cardiovascular Institute
Northwestern Memorial Hospital
Chicago, IL
Sandeep Nathan, MD, MSc, FACC, FSCAI
Assistant Professor of Medicine
Pritzker School of Medicine
Director, Interventional Cardiology Fellowship Program
University of Chicago Medical Center
Chicago, IL
Yerem Yeghiazarians, MD
Associate Professor of Clinical Medicine
University of California, San Francisco
Co-Director, Adult Cardiac Catheterization Laboratory
Director, Cardiology Peripheral Interventional Program
Director, Translational Cardiac Stem Cell Program
San Francisco, CA
Learning Objectives
- Describe current guideline recommendations for the use of antiplatelet therapies in the management ACS patients, including the implications of the latest STEMI guidelines on clinical practice.
- Formulate an approach to the use of evidence-based antiplatelet therapies in the ACS patient undergoing percutaneous coronary intervention, including timing and dosage considerations.
- Apply research data on antiplatelet therapy in ACS patients as it relates to genetic polymorphism, and discuss the latest evidence on concomitant use of thienopyridines and proton pump inhibitors.
- Outline at least two considerations related to the long-term safety and efficacy of various antiplatelet agents in patients who have had a coronary event.
Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education. Pri-Med Institute, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians, the Accreditation Council for Pharmacy Education (ACPE) as a provider for continuing pharmacy education, and the American Academy of Nurse Practitioners (AANP) and the American Nursing Credentialing Center (ANCC) to provide continuing nursing education. Pri-Med Institute designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credits commensurate with the extent of their participation.
Grant Support
These programs are supported by an education grant from sanofi-aventis.
Registration
To register visit www.pri-med.com